Skip to main content
SpringerLink
Log in

New Dopamine Receptor Agonists in Heart Failure and Hypertension

Implications for Future Therapy

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Aronson S, Roth S, Glock D, Goldberg LI. Preservation of renal blood flow during controlled hypotension with fenoldopam. Clinical Research 35: 881A, 1987

    Google Scholar 

  • Bass AS, Kohli JD, Lubbers N, Goldberg LI. Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog. Journal of Pharmacology and Experimental Therapeutics 242: 940–944, 1987

    PubMed  CAS  Google Scholar 

  • Bayliss J, Thomas L, Poole-Wilson P. Acute hemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: comparison with dobutamine, captopril and nitrate. Journal of Cardiovascular Pharmacology 9: 551–554, 1987

    Article  PubMed  CAS  Google Scholar 

  • Brown RA, Dixon J, Farmer JB, Hall JC, Humphries RG, et al. Dopexamine: a novel agonist at peripheral dopamine receptors and beta2-adrenoceptors. British Journal of Pharmacology 85: 599–608, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Brown RA, Farmer JB, Hall JC, Humphries RG, O’Connor SE, et al. The effects of dopexamine on the cardiovascular system of the dog. British Journal of Pharmacology 85: 609–619, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Carey RM, Stote RM, Dubb JW, Townsend LH, Rose Jr CE, et al. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. Journal of Clinical Investigation 74: 2198–2207, 1984

    Article  PubMed  CAS  Google Scholar 

  • Dawson JR, Thompson DS, Signy M, Juul SM, Turnbill P, et al. Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. British Heart Journal 54: 313–320, 1985

    Article  PubMed  CAS  Google Scholar 

  • Del Cass L, Bolognesi R, Cucchini F, Fappani A, Riva S, et al. Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy. Journal of Cardiovascular Pharmacology 5: 249–253, 1983

    Article  Google Scholar 

  • D’Orio V, El Allaf D, Juchmes J, Marcelle R. The use of low doses of dopamine in intensive care medicine. Archives Internationales de Physiologie et de Biochimie 92: 511–520, 1986

    Google Scholar 

  • El Allaf D, Cremers S, D’Orio V, Carlier J. Combined hemodynamic effects of low dose dopamine and dobutamine in patients with acute infarction and cardiac failure. Archives Internationales de Physiologie et de Biochimie 92: S49–S55, 1986

    Google Scholar 

  • Elliott WJ, Weber RR, Nelson KS, Murphy MB. Salutary renal effects in severe hypertension. Abstract no. 1070. American Journal of Hypertension 1: 22A, 1988

    Google Scholar 

  • Fitton A, Benfield P. Dopexamine hydrochloride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 39: 308–330, 1990

    Article  PubMed  CAS  Google Scholar 

  • Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacological Reviews 24: 1–29, 1972

    PubMed  CAS  Google Scholar 

  • Goldberg LI. Dopamine: clinical uses of an endogenous catecholamine. New England Journal of Medicine 291: 707–710, 1974

    Article  PubMed  CAS  Google Scholar 

  • Goldberg LI, Hsieh Y-Y, Resnekov L. Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Progress in Cardiovascular Diseases 4: 327–340, 1977

    Article  Google Scholar 

  • Goldberg LI, Rajfer SI. Dopamine receptors: applications in clinical cardiology. Circulation 72: 245–248, 1985

    Article  PubMed  CAS  Google Scholar 

  • Goldberg LI, Sonneville PF, McNay JL. An investigation of the structural requirements for dopamine-like renal vasodilation: phenylethylamines and apomorphine. Journal of Pharmacology and Experimental Therapeutics 163: 188–197, 1968

    PubMed  CAS  Google Scholar 

  • Hahn RA, Wardell Jr JR, Sarau HM, Ridley PT. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. Journal of Pharmacology and Experimental Therapeutics 223: 305–311, 1982

    PubMed  CAS  Google Scholar 

  • Henwood JM, Todd PA. Ibopamine: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 36: 11–31, 1988

    Article  PubMed  CAS  Google Scholar 

  • Itoh H, Kohli JD, Rajfer SI, Goldberg LI. Comparison of the cardiovascular actions of dopamine and epinine in the dog. Journal of Pharmacology and Experimental Therapeutics 233: 87–93, 1985

    PubMed  CAS  Google Scholar 

  • Kohli JD, Metra M, Satoh Y, Goldberg LI. Dopamine receptors in the stellate ganglion of the dog. European Journal of Pharmacology 164: 265–272, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kohli JD, Weder AB, Goldberg LI, Ginos JZ. Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors. Journal of Pharmacology and Experimental Therapeutics 213: 370–374, 1980

    PubMed  CAS  Google Scholar 

  • Lass NA, Glock D, Goldberg LI. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Circulation 78: 1310–1315, 1988

    Article  PubMed  CAS  Google Scholar 

  • McDonald Jr RH, Goldberg LI. Analysis of the cardiovascular effects of dopamine in the dog. Journal of Pharmacology and Experimental Therapeutics 140: 60–66, 1963

    CAS  Google Scholar 

  • McNay JL, MacCannell KL, Meyer MB, Goldberg LI. Hypotensive effect of dopamine in dogs and hypertensive patients after phenoxybenzamine. Journal of Clinical Investigation 45: 1045, 1966

    Google Scholar 

  • Mercuro G, Rivano AC, Ruscazio M, Tocco L, Cherchi A, et al. Effects of long-term treatment with dihydroergotoxine (hydergine) on blood pressure and plasma norepinephrine in essential hypertensive patients. In Biggio et al. (Eds) Modulation of central and peripheral transmitter function, Fidia Research Series, Symposia in Neuroscience III, pp. 189–193, Liviana Press, Padova, 1986

    Google Scholar 

  • Mercuro G, Rossetti ZL, Tocco L, Rivano CA, Cherchi A, et al. Bromocriptine reduces plasma noradrenaline and 3,4-dihydroxyphenylacetic acid in normal and hypertensive subjects. European Journal of Pharmacology 27: 671–675, 1985

    Article  CAS  Google Scholar 

  • Murphy MB, McCoy CE, Weber RR, Frederickson ED, Douglas FL, et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation 76: 1312–1318, 1987

    Article  PubMed  CAS  Google Scholar 

  • Murphy MB, Weber RR, Nelson N, Goldberg LI. The role of alpha-adrenoceptor blockade in the antihypertensive effects of fenoldopam in humans. Clinical Pharmacology and Therapeutics 44: 49–55, 1988

    Article  PubMed  CAS  Google Scholar 

  • Ohlstein E, Zabko-Potapovich B, Bzekowitz BA. The DA1 receptor agonist fenoldopam (SKF 82526) is also an α2-adrenoceptor antagonist. European Journal of Pharmacology 118: 321–329, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rajfer SI, Anton AH, Rossen JD, Goldberg LI. Beneficial hemodynamic effects of oral levodopa in heart failure: relation to generation of dopamine. New England Journal of Medicine 310: 1357–1362, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rajfer SI, Rossen JD, Douglas FL, Goldberg LI, Karrison T. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyl dopamine and to plasma norepinephrine levels. Circulation 73: 740–748, 1986

    Article  PubMed  CAS  Google Scholar 

  • Rajfer SI, Rossen JD, Nemanich JW, Douglas FL, Davis F, et al. Sustained hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines. Journal of the American College of Cardiology 10: 1286–1293, 1987

    Article  PubMed  CAS  Google Scholar 

  • Stote RM, Dubb JW, Familiar RG, Lee K, Alexander F. Endocrine effects of fenoldopam (SK&F 82526/J) — a dopamine agonist. Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics, Washington DC, pp. 378–390, 1983

  • Tan L-B, Littler WA, Murray RG. Beneficial hemodynamic effects of intravenous dopexamine in patients with low-output heart failure. Journal of Cardiovascular Pharmacology 10: 280–286, 1987

    Article  PubMed  CAS  Google Scholar 

  • Taylor AA, Fennell WH, Rudd CO, Pool JL, Nelson EB, et al. Propylbutyldopamine: mechanism of blood pressure lowering in hypertensive patients. Hypertension 6 (Suppl. I): I-–40–I-–45, 1984

    Google Scholar 

  • White WB, Radford MJ, Gonzalez FM, Weed SG, McCabe EJ, et al. Selective dopamine1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. Journal of the American College of Cardiology 11: 1118–1123, 1988

    Article  PubMed  CAS  Google Scholar 

  • Whitworth JA, MacDonald I, Kincaid-Smith P. Bromocriptine in mild to moderate hypertension. Australian and New Zealand Journal of Medicine 17: 457–458, 1987

    Article  PubMed  CAS  Google Scholar 

  • Young JB, Leon CA, Pratt CM, Suarez JM, Aronoff RD, et al. Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. Journal of the American College of Cardiology 6: 792–796, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ziemniak J, Dubb J, Stote R, Trotman C, Yang W, et al. Pharmacokinetic interaction between fenoldopam and acetaminophen: competition for sulfate conjugation. Abstract no. 32. Clinical Pharmacology and Therapeutics 37: 240, 1985

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Committee on Clinical Pharmacology, Departments of Pharmacological and Physiological Sciences, Medicine and Pediatrics, University of Chicago, 947 East 58th Street, Chicago, Illinois, 60637, USA

    Patrick T. Horn &  Michael B. Murphy

Authors
  1. Patrick T. Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael B. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horn, P.T., Murphy, M.B. New Dopamine Receptor Agonists in Heart Failure and Hypertension. Drugs 40, 487–492 (1990). https://doi.org/10.2165/00003495-199040040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199040040-00001

Keywords

Search

Navigation